一分钟看懂
这是一项关于晚期恶性肿瘤的I 期研究，登记的药物或干预包括TQB6426 for Injection，当前状态为招募中。登记地点显示中国合肥、北京、福州、广州等城市有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
TQB6426 for Injection · I 期
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- The First Affiliated Hospital of Anhui Medical University · 合肥
- Peking University First Hospital · 北京
- Fujian Provincial Hospital · 福州
- ZhuJiang Hospital of Southern Medical University · 广州
- Harbin Medical University Cancer Hospital · 哈尔滨
- Henan Cancer Hospital · 郑州
- Hunan Cancer Hospital · 长沙
- Renji Hospital, Shanghai Jiao Tong University School of Medicine · 上海
公开的入选条件
- 1. Study participants voluntarily enroll in this study, sign the informed consent form, and demonstrate good treatment compliance.
- 2. Age ranging from 18 to 75 years (calculated based on the date of informed consent signature).
- 3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- 4. Estimated survival time exceeding 12 weeks.
- 5. Child-Pugh liver function score ≤ 7 points (Class B).
- 6. Per RECIST v1.1 criteria, at least one evaluable tumor lesion must be identified as a target lesion. Lesions previously treated with local therapy (transarterial embolization, transarterial chemoembolization, transarterial radioembolization, surgery, radiof
- 7. Participants must provide qualified tumor tissue specimens, or consent to submit archived tumor tissue samples, or undergo percutaneous core biopsy or surgical biopsy on previously unirradiated tumor lesions to supply specimens for central laboratory biomar
- 8. Dose-escalation phase: Advanced solid tumors confirmed via histopathological or cytological examination with failure of prior standard systemic anti-tumor therapies.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT07730190；登记信息更新于 2026-09-15。